Introduction
============

A widely accepted definition of pain was developed by a taxonomy task force of the International Association for the Study of Pain: "Pain is an unpleasant sensory and emotional experience that is associated with actual or potential tissue damage or described in such terms." A key feature of this definition is "pain is always subjective". Pain management in neonates should not just be driven by ethics or empathy, but should be viewed as part of normal medical and nursing care.[@b1-jpr-12-299] Noxious stimulation in the form of venipuncture or heel prick produces a cortical response in both preterm and term newborn infants, measured as an increase in total hemoglobin concentration in the contralateral somatosensory cortex, and nociceptive reflexes, measurable as lower-limb withdrawal and flexor-muscle activity.[@b2-jpr-12-299] Pain is a particular problem for newborns: early in life, it elicits specific behaviors, activates the somatosensory cortex, and stimulates neuroendocrine stress responses, thus leading to short- and long-term clinical consequences.[@b1-jpr-12-299]--[@b4-jpr-12-299]

Studies have demonstrated a relationship between pain degree and oxidative stress in healthy full-term newborns at their first pain exposure. We have also reported that sensorial saturation reduces pain score together with pain-related oxidative stress.[@b5-jpr-12-299] Sensorial saturation is a technique used during heel prick in which mothers simultaneously attract their infant's attention by massaging the cheek, speaking to the baby gently, and administering oral glucose.[@b6-jpr-12-299]

Multiple trials and systematic reviews have highlighted beneficial analgesic effects of 24% sucrose for neonates undergoing invasive procedures.[@b7-jpr-12-299]--[@b10-jpr-12-299] Sucrose in combination with other nonpharmacological interventions, such as nonnutritive sucking (NNS) seems to be more effective than sucrose alone.[@b10-jpr-12-299] Nevertheless, there is limited evidence regarding its analgesic efficacy and safety in healthy term newborns beyond the first week of life. In this comparative study, we tested the hypothesis that oral administration of 24% sucrose associated with NNS in healthy newborns receiving venipuncture beyond the first week of life controls pain and pain-associated variation of heart rate (HR) and noninvasive oxygen saturation (SpO~2~) better that oral administration of 10% glucose associated with NNS.

Methods
=======

Participants
------------

A randomized double-blinded case--control pilot study was conducted from February to September 2017 at the neonatal intensive care unit (NICU) of Santobono-Pausilipon Hospital in Naples, Italy, following research-ethics approval and written informed consent from the families. The study was conducted in accordance with the Declaration of Helsinki. Inclusion criteria were Italian neonates 37--42 weeks gestational age at birth and \>1 week old at the time of the intervention with body weight 2,500--4,500 g and able to feed orally. Exclusion criteria were concurrent use of pharmacological pain strategies, neonates with a contraindication for sucrose administration (eg, too ill or unstable for neonatologist assessment, unable to swallow, pharmacologically muscle-relaxed), and inability to assess behavioral responses to pain accurately (eg, neonate's face blocked with tape). Patients undergoing painful, stressful procedures or with congenital or perinatal diseases were excluded. Patients born from smoking mothers and those with maternal diabetes, placenta abruption, chronic pathologies, or using drugs/alcohol during pregnancy and infants with fetal growth restriction, fetal malformations, genetic/metabolic disorders, clinical signs of maternal, or fetal infection were also excluded ([Figure 1](#f1-jpr-12-299){ref-type="fig"}).

Newborns were enrolled after their first week of life during routine control for hyperbilirubinemia or minor surgery in the neonatology ward. Routine controls were carried out in a separate room with 2,000 lx between 9 and 10 am.[@b11-jpr-12-299] Another room was used for the treatment intervention and projected to reduce sources of stress, with instrument noise set at \<45 dB and 10--600 lx.[@b12-jpr-12-299]

Newborns were randomly assigned to receive oral sucrose and NNS (treated group (\[TG\]) or comprised the control group (CG), and randomization was performed using a privacy-protected randomization hospital service. In the TG, each infant received both 1 mL 24% sucrose (Antalbimbo; Orsana, Rome, Italy) orally via syringe 1 minute before venipuncture and 1 mL during the procedure. A pacifier was offered to all neonates immediately following sucrose administration to facilitate NNS, which has been shown to enhance efficacy.[@b10-jpr-12-299] In the CG, each infant received 1 mL 10% glucose orally via syringe with a pacifier 1 minute before venipuncture and during the procedure. Oral solutions were administered drop by drop by an expert caregiver via syringe over the anterior surface of the tongue, allowing for individual neonate swallowing rates over a period of 1 minute. Outcome measures (HR, SpO~2~, Neonatal Infant Pain Scale \[NIPS\]) were obtained prior to (T0), during (T1), and 1 minute after venipuncture (T2) in each group. Neonate behavior was scored using the NIPS. Investigators and caregivers were blinded to group assignment.

Instruments
-----------

Data were recorded using a database (Excel 2007) by a pediatric nurse who was aware of the study aims. Parameters collected were sex, gestational age, days of life, body weight, HR at T0, T1, and T2, SpO~2~ at T0, T1, and T2, and NIPS scores at T1.

Another pediatric nurse aware of the study aims measured the body weight of the newborns with a Seca 354 baby scale and collected NIPS scores after 6 months of NIPS practice. Vital parameters were collected with a Nellcor bedside SpO~2~ patient-monitoring system. The research nurse placed pulse oximetry probes on the right wrist of every neonate to record HR and SpO~2~ continuously and positioned herself in front of the newborn to capture facial movements.

Outcome measures
----------------

The primary outcome was pain intensity measured with the NIPS, a behavioral scale validated by Lawrence et al in 1993[@b13-jpr-12-299] that comprises six items (facial expression, cry, breathing, arms, legs, and state of arousal). Caregivers can rate items from 0 (relaxed) to 1 (different than basal) and from 0 (absent) to 2 (vigorous) for cry. A score ≥4 indicates that the newborn feels pain.

The secondary outcome was frequency of a priori-specified adverse event/tolerance criteria (HR \>240 beats/minute or HR \<80 beats/minute for \>20 seconds, SpO~2~ \<80% for \>20 seconds, no spontaneous respirations for \>20 seconds, and choking/gagging). Adverse-event data were collected by the research nurse during the intervention, and she also kept a record of "rescue doses" administered (ie, additional doses of sucrose or glucose) if the neonate became overly distressed during the procedure.

Statistical analysis
--------------------

Statistical analysis was performed by a statistician who was aware of the study aim using SPSS version 20.0 (IBM, Armonk, NY, USA). Normal distribution of the data was evaluated by Kolmogorov--Smirnov test. Parametric and nonparametric data were evaluated by one-way ANOVA or *c*^2^ test, respectively. Changes in HR and SpO~2~ from T0 to T2 were assessed by mixed ANOVA for repeated measures. HR and SpO~2~ were analyzed by reciprocal transformation because of lack of homogeneity. Differences between NIPS scores were evaluated by Mann--Whitney *U* test. All data with *P*\<0.05 were considered significant.

Results
=======

A total of 66 term newborns were enrolled for the study and randomly assigned to each group (33 in CG and 33 in TG). Demographic characteristics in the two groups were matched and comparable ([Table 1](#t1-jpr-12-299){ref-type="table"}). The groups started from similar conditions for HR and SpO~2~ at T0 ([Table 2](#t2-jpr-12-299){ref-type="table"}). Changes in vital parameters between groups are reported in [Table 2](#t2-jpr-12-299){ref-type="table"} and [Figures 2](#f2-jpr-12-299){ref-type="fig"}[](#f3-jpr-12-299){ref-type="fig"}--[4](#f4-jpr-12-299){ref-type="fig"}. NIPS scores in both groups were \<4 at T0; however, scores were significantly lower in TG (range 1--2 and median 0) compared with CG at T1 (range 5--7 and median 6). Finally, 100% of term newborns in CG had a score ≥4 (range 4--6 and median 5) and 100% of those in TG showed a score \<4 at T2 (range and median 0). There were no reported adverse events defined by a priori criteria among neonates.

Discussion
==========

In this study, we report that oral administration of 1 mL 24% sucrose prior to and during a single painful procedure appears to be effective in significantly reducing pain in term neonates at the first experience of procedural pain beyond the first week of life. As we know, inadequate pain management in neonatal life is a major impediment to proper neurodevelopment: it alters pain thresholds, physiological responses, and stress- or pain-related behavior beyond early infancy.[@b14-jpr-12-299] Nonpharmacological pain control for infants has been recently supported. Although the impacts of nonpharmacological interventions have been assessed extensively, they were evaluated mostly in sick babies of different postnatal ages using different treatments and pain assessments that yielded ununiform data. Rioualen et al compared sucrose solution or breast-feeding before venipuncture for neonatal screening in healthy 3-day-old term neonates.[@b15-jpr-12-299] They used the Neonatal Facial Coding System to assess pain reactions and reported any difference between sucrose administration and breast-feeding on cortical activity measured by NIRS during a painful procedure. Stevens et al reported that sucrose was effective to treat pain associated with a single heel lance in term neonates admitted to tertiary NICUs.[@b10-jpr-12-299] Efe et al studied three random groups (sucrose, breastfeeding, and control) of term newborn infants at 48 hours of life and found similar pain responses in the sucrose and breast-feeding groups using the NIPS. They also reported that newborns given sucrose spent less time crying than breast-fed newborns.[@b16-jpr-12-299]

Thakkar et al demonstrated that sucrose in combination with NNS was more effective than sucrose alone in controlling pain in full-term newborns undergoing heel-stick procedures in the first hours of life,[@b3-jpr-12-299] and this finding led us to evaluate its effect in a population of newborns over the first week of life. No studies have reported data regarding the efficacy of 24% sucrose for analgesia in healthy newborns over the first week of life.

Our results may represent one of the most important future perspectives in this field, evaluating the efficacy of oral 24% sucrose for complete analgesia in term infants over time. Few studies have evaluated HR and SpO~2~ responses after noxious stimulation in term infants beyond the NICU setting. The use of HR and SpO~2~ as outcome measures and the evidence that a proper analgesic procedure can protect patients from pain-related variation in vital parameters represents the second main finding of our paper as these physiological responses to pain objectify recognition and care of pain during unpleasant experiences. Furthermore, the fact that changes in HR and SpO~2~ are not significant in infants treated with 24% sucrose even after 1 minute from venipuncture demonstrates a possible protective effect from repercussions subsequent to the pain stimulus.[@b17-jpr-12-299]

Previously, we found that sensorial saturation, a noninvasive, easily performed, and reproducible technique, was effective for analgesia during heel prick in neonates.[@b6-jpr-12-299] During sensorial saturation, mothers simultaneously attract their infant's attention by massaging the cheek, speaking to the baby gently, and administering 1 mL 10% oral glucose.[@b6-jpr-12-299] There is evidence that sweet solutions \<18% are ineffective in reducing infant pain optimally.[@b10-jpr-12-299] In this study, we used 24% sucrose associated with NNS to control pain, and we verify complete analgesia through a reduction in pain-related variations in HR and SpO~2~ in term newborns.

This study has some limitations. It did not include a control group receiving a placebo (sterile water). However, to assign infants randomly to a placebo and deny them a treatment would have been unethical. The small sample size does not allow us to reach conclusive results, but the findings are significant and pave the way to widespread use of sucrose 24% associated with NNS.

In conclusion, 1 mL 24% oral sucrose with NNS prior to and during venipuncture is a noninvasive, adequately safe, and reproducible tool for complete analgesia in healthy term newborns over the first week of life. It also protects against pain-related variations in HR and SpO~2~. Replication of this study in a large trial is needed to implement coverage of pain control in babies. New research will address barriers to scaling up and evaluate 24% sucrose efficacy immediately after birth at the time of intramuscular injection of vitamin K for vitamin K deficiency-related bleeding prophylaxis and beyond the neonatal period.
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###### 

Clinical characteristics of study population

  Clinical characteristics                        Treated (n=33)   Controls (n=33)   *P*-value
  ----------------------------------------------- ---------------- ----------------- -----------
                                                                                     
  Sex[a](#tfn2-jpr-12-299){ref-type="table-fn"}   Male 72%         Male 67%          0.592
  Gestational age (weeks)                         38.53±1.49       38.91±1.45        0.309
  Body weight at birth (g)                        3.035±0.55       3.203±0.65        0.267
  Days of life                                    22.40±6.82       23.36±7.02        0.820
  Heart rate, T0                                  143±16.8         147±12.5          0.181
  SpO~2~, T0                                      99.48±0.56       99.57±0.61        0.538

**Notes:** Data expressed as mean±SD.

Percentages reported for nominal data.

###### 

Change in vital parameters from T0 (before) to T2 (after venipuncture) **Vital**

  Vital parameters   Time   n              Control group   Treated group   F(1,60)   *P*-value   *R*-value
  ------------------ ------ -------------- --------------- --------------- --------- ----------- -----------
  **Heart rate**                                                                                 
  T0 vs T1           T0     29             143±16.8        147±12.5        69.572    \<0.05      0.73
  T1                 33     191.57±16.94   159.48±12.46                                          
  T1 vs T2           T1     33             191.57±16.94    159.48±12.46    16.312    \<0.05      0.46
  T2                 33     160.51±17.65   147.42±12.05                                          
  **SpO~2~**                                                                                     
  T0 vs T1           T0     33             99.48±0.56      99.57±0.61      215.443   \<0.05      0.88
  T1                 33     89.93±4.11     98.39±0.89                                            
  T1 vs T2           T1     33             89.93±4.11      98.39±0.89      47.629    \<0.05      0.66
  T2                 29     97.39±1.05     99.51±0.62                                            

**Notes:** Data expressed as mean±SD.
